公开(公告)号：US20190192628A1

公开(公告)日：2019-06-27

申请号：US16297494

申请日：2019-03-08

Applicant: AMGEN INC.

Inventor： Gunasekaran KANNAN ,  Jennifer LAVALLEE ,  Frederick W. JACOBSEN

IPC: A61K38/18 ,  C07K16/00 ,  A61K47/68 ,  C07K14/475

CPC classification number: A61K38/18 ,  A61K47/48376 ,  A61K47/6801 ,  C07K14/475 ,  C07K16/00 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2319/30

Abstract: This disclosure provides polypeptides comprising an antibody Fc region having a deletion of one or more cysteine residues in the hinge region and substitution with a sulfhydryl-containing residue of one or more CH3-interface amino acids. Also, provided are Fc-fusion proteins and antibodies containing said polypeptides, nucleic acids and vectors encoding said polypeptides, along with host cells and methods for making said polypeptides.

公开(公告)号：US20190008974A9

公开(公告)日：2019-01-10

申请号：US14967167

申请日：2015-12-11

Applicant: Amgen Inc.

Inventor： Richard J. ARMITAGE ,  Michelle BLAKE ,  William C. FANSLOW, III ,  Jason Charles O'NEILL ,  Gunasekaran KANNAN ,  Jiangchun XU ,  Mark Edward TOMETSKO

IPC: A61K47/48 ,  C07K16/28 ,  A61K31/395 ,  A61K39/395 ,  A61K45/06

Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.

公开(公告)号：US20180079790A1

公开(公告)日：2018-03-22

申请号：US15826442

申请日：2017-11-29

Applicant: Amgen Inc.

Inventor： Yumei XIONG ,  Yi ZHANG ,  Jackie Z. SHENG ,  Agnes Eva HAMBURGER ,  Murielle M. VENIANT-ELLISON ,  Grant SHIMAMOTO ,  Xiaoshan MIN ,  Zhulun WANG ,  Jie TANG ,  Gunasekaran KANNAN ,  Marissa MOCK ,  Kenneth William WALKER

IPC: C07K14/475

CPC classification number: C07K14/475 ,  C07K2319/30

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

公开(公告)号：US20170306033A1

公开(公告)日：2017-10-26

申请号：US15511176

申请日：2015-09-15

Applicant: AMGEN INC.

Inventor： Gunasekaran KANNAN ,  Ling LIU ,  Edward J. BELOUSKI ,  Cen XU

IPC: C07K16/28

CPC classification number: C07K16/2869 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/70 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to bispecific antigen binding proteins that are capable of binding to both the human CGRP receptor and the human PAC1 receptor. Pharmaceutical compositions comprising the bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the bispecific antigen binding proteins to ameliorate or treat conditions associated with the two receptors, such as chronic pain, migraine, and cluster headache, are also described.

公开(公告)号：US20170165373A1

公开(公告)日：2017-06-15

申请号：US14967167

申请日：2015-12-11

Applicant: Amgen Inc.

Inventor： Richard J. ARMITAGE ,  Michelle BLAKE ,  William C. FANSLOW, III ,  Jason Charles O'NEILL ,  Gunasekaran KANNAN ,  Jiangchun XU ,  Mark Edward TOMETSKO

IPC: A61K47/48 ,  A61K45/06 ,  A61K39/395 ,  C07K16/28 ,  A61K31/395

CPC classification number: A61K39/3955 ,  A61K31/395 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6867 ,  A61K2039/505 ,  A61K2039/572 ,  C07K16/18 ,  C07K16/2878 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.

公开(公告)号：US20140343252A1

公开(公告)日：2014-11-20

申请号：US14209914

申请日：2014-03-13

Applicant: Amgen Inc.

Inventor： Marc A. GAVIN ,  Gunasekaran KANNAN ,  Li LI ,  Joshua T. PEARSON ,  Margaret KAROW

IPC: C07K14/55 ,  C07K16/00

CPC classification number: C07K14/55 ,  A61K38/00 ,  C07K16/00 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/71 ,  C07K2317/94 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.

Abstract translation: 本文提供了IL-2突变蛋白和IL-2突变蛋白Fc-融合分子，其优先扩增和激活T调节细胞并且适于大规模生产。 本文还提供了缺乏或具有高度降低的效应子功能和高稳定性的变体人IgG1 Fc分子，尽管在N297缺乏糖基化。 此外，本文提供了当在哺乳动物细胞中表达时被糖基化的接头肽。